Drug Trial Radar · NCT07498335
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Aug 6, 2026
Primary completion
Sep 15, 2031
Study completion Dec 13, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Conditions
- Berger Disease
- Bergers Disease
- IgA Nephropathy
- Immunoglobulin A Nephropathy
- Primary IgAN
- Nephritis IgA Type, Nephropathy IgA Type
Interventions
Drug: AtrasentanDrug
* 104 Weeks - Film-coated tablet * Other Names: Atrasentan Hydrochloride ABT-627
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Proteinuria at Week 36Time frame: Baseline and 36 weeks
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Hackensack Meridian Health
Neptune City, New Jersey · Not yet recruiting
Cincinnati Childrens Hospital MC
Cincinnati, Ohio · Not yet recruiting
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma · Not yet recruiting
University of Tennessee Health Science Center- Le Bonheur Research Center
Memphis, Tennessee · Not yet recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Xi'an, China · Recruiting
Novartis Investigative Site
Medellín, Antioquia, Colombia · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Bron, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Toulouse, France · Recruiting
Novartis Investigative Site
Chiba, Japan · Recruiting
Novartis Investigative Site
Fukuoka, Japan · Recruiting
Novartis Investigative Site
Nagoya, Aichi-ken, Japan · Recruiting
Novartis Investigative Site
Kanazawa, Ishikawa-ken, Japan · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Cadiz, Andalusia, Spain · Recruiting
Novartis Investigative Site
Taipei, Taiwan · Recruiting
Novartis Investigative Site
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.